TEVA
HEALTHCARETeva- Pharmaceutical Industries Ltd
$36.34+0.48 (+1.34%)PRE
Live · NYSE · May 9, Close
AI Insight
What's Moving TEVA Today?
No stock-specific AI insight has been generated for TEVA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$14.99$37.35
$36.34
Fundamentals
Market Cap$41.9B
P/E Ratio26.9
EPS$1.34
Dividend Yield—
Dividend / Share—
ROE0.2%
Profit Margin0.1%
Debt / Equity—
Trading
Volume6.9M
Avg Volume (10D)—
Shares Outstanding1.16B
TEVA News
28 articles- Alvotech Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Solid Earnings Reflect Teva Pharmaceutical Industries' (NYSE:TEVA) Strength As A BusinessYahoo Finance·May 6, 2026
- Teva to Present at the BofA Securities Health Care ConferenceYahoo Finance·May 4, 2026
- How The Investment Story For Teva Pharmaceutical Industries (TEVA) Is Shifting With New Analyst FocusYahoo Finance·May 4, 2026
- Teva Pharmaceutical Industries Q1 Earnings: AUSTEDO Surges as Teva Plots $700M Emalex BuyoutMarketbeat·May 4, 2026
- Is Deckers Outdoor Corporation (DECK) A Good Stock To Buy Now?Yahoo Finance·May 3, 2026
- Is Teva Pharmaceutical Industries Limited (TEVA) A Good Stock To Buy Now?Yahoo Finance·May 3, 2026
- Teva (TEVA) Enters a New $700 Million Acquisition DealYahoo Finance·May 2, 2026
- Teva Pharmaceutical Industries Q1 Earnings Call HighlightsMarketbeat·May 2, 2026
- Teva Pharmaceutical Industries Positioned for Re-Rating on Growth Drivers, UBS SaysYahoo Finance·Apr 30, 2026
- A Look At Teva (NYSE:TEVA) Valuation After Robust First Quarter 2026 Earnings ReactionYahoo Finance·Apr 30, 2026
- TEVA Q1 Earnings Top Estimates, Branded Drugs Drive Revenues, Stock UpYahoo Finance·Apr 30, 2026
- Analysis of the 2026 Oral Solid Dosage Contract Manufacturing Market - Scalable Pharma Solutions & Generic Demand Drive $59.05 Billion Forecast for 2030Yahoo Finance·Apr 30, 2026
- Teva's 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond TargetsYahoo Finance·Apr 30, 2026
- Teva signs off $900m Emalex buyout amid strategic pipeline boosting ployPharmaceutical-technology·Apr 30, 2026
- Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't?Motley Fool·Apr 30, 2026
- Teva Pharmaceutical Industries Ltd (TEVA) Q1 2026 Earnings Call Highlights: Strong Innovative ...Yahoo Finance·Apr 30, 2026
- Teva Pharmaceuticals (TEVA) Soars 12% as Profits Hit New RecordYahoo Finance·Apr 30, 2026
- Teva Surges 12% — And It's Not Completely Tied To EarningsYahoo Finance·Apr 29, 2026
- Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - Kaken Pharma, Novartis, Glenmark Pharma, Sun Pharma, Teva Pharmaceutical, Bayer, and GaldermaGlobeNewswire Inc.·Apr 23, 2026
- Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research Annual MeetingGlobeNewswire Inc.·Apr 17, 2026
- Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care PartnersGlobeNewswire Inc.·Apr 15, 2026
- Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable ClinicsGlobeNewswire Inc.·Apr 14, 2026
- Crohn's Disease Eight-Market Drug Forecast and Market Analysis Report 2025-2026: Novel MOAs Will Provide Market Shifts Throughout the Forecast Period to 2032GlobeNewswire Inc.·Apr 10, 2026
- Viatris at $14: A Double-Digit FCF Yield Hiding in Plain SightInvesting.com·Apr 2, 2026
- Teva gewinnt an Dynamik im Biosimilar-Geschäft mit der FDA-Zulassung für PONLIMSI™ (Denosumab-adet) und der Annahme von parallelen Zulassungsanträgen für einen Biosimilar-Kandidaten zu Xolair® (Omalizumab)GlobeNewswire Inc.·Mar 30, 2026
- Teva gagne du terrain dans le domaine des médicaments biosimilaires grâce à l’approbation accordée par la FDA pour PONLIMSI™ (dénosumab-adet) et à l’acceptation d’un double dossier pour un candidat biosimilaire à Xolair® (omalizumab)GlobeNewswire Inc.·Mar 30, 2026
- Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)GlobeNewswire Inc.·Mar 30, 2026
All 28 articles loaded
Price Data
Open$36.37
Previous Close$35.86
Day High$36.52
Day Low$35.62
52 Week High$37.35
52 Week Low$14.99
52-Week Range
$14.99$37.35
$36.34
Fundamentals
Market Cap$41.9B
P/E Ratio26.9
EPS$1.34
Dividend Yield—
Dividend / Share—
ROE0.2%
Profit Margin0.1%
Debt / Equity—
Trading
Volume6.9M
Avg Volume (10D)—
Shares Outstanding1.16B
About Teva- Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNYSE
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—